Breast Cancer Survivorship of Patients after Receiving Anti-Hormonal Therapy in Khon Kaen Hospital

Abstract

This retrospective descriptive research aimed to study the survivorship of breast cancer patients after receiving oral antiretroviral therapy. The sample consisted of 620 patients with breast cancer receiving oral antiretroviral therapy who registered during the period between    January 1, 2005, to December 31, 2016, and had been followed up until February 28, 2018, at Khon Kaen center of excellence for cancer. Data were collected using a patient form. Data were analyzed using frequency, percentage, standard deviation and the Kaplan – Meier method in the analysis of survival rates. Log-rank test was used in statistical tests.

Results showed that the average age was 53.4 (SD=10.8) years, 41.90 percent received Tamoxifen only, 22.5 percent received Letozole alone and 35.55 percent had Tamoxifen together with Letozole, with the total survival rates at periods 1, 3 and 5 years equal to 96, 86 and 78 percent, respectively. The overall survival period after receiving antiretroviral therapy was 5.6 years. The two groups receiving the drugs together (Tamoxifen with Letozole) had the highest survival rate of 4.6 years. The overall survival rate at 5 years was equal to 74.7 percent (95% CI: = 68.03 to 80.19), followed by the group receiving the same type of drug (Letozole, 3.2 years). The overall 5-year survival rate was 62.9 percent (95% CI:=53.55 to 70.94). When comparing the differences of survival in each factor, it was found that the breast cancer stage 3 had a survival rate of 3.5 years and a survival rate of 5 years was 65.8 percent (95% CI: = 57.71 to 72.63), which was higher than the stage 4 group.

From the results, the study can be applied to find a guideline for survivorship care plan that increases the chances of survivorship of breast cancer patients who received anti-hormone drugs.